3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis
Assessment of 3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis in Cancer Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18years.
- Patient has initial or recurrent disease
- Undergoing external beam radiotherapy at the Mayo Clinic Rochester campus Note: Patients who are undergoing concurrent chemotherapy are eligible
- Ability to complete questionnaire(s) by themselves or with assistance
- Provide informed written consent
- Willing to consent for photography of radiation field
- Available to return to Mayo Clinic in within 1 week post treatment for assessment (+/- 7 days).
- At risk for developing ≥ grade 2 dermatitis radiation as determined by treating Radiation Oncology clinician
- Biologic effective dose of >42 Gy10 as calculated using the web site EQD2.com.
Exclusion Criteria:
- Unable to provide informed consent
- Patients with active rash, pre-existing dermatitis, lupus or scleroderma within the treatment area that may make skin assessment for the study difficult
- Known history of developing an allergic reaction after using a product containing cyanoacrylate or acrylates
- Subject has a medical condition that in the opinion of the investigator should exclude him/her from participating in the study
- Subject has been enrolled in an investigational study where product was applied to the proposed study site within 30 days of the screening visit
- The skin area affected by radiation requires treatment with a concomitant medication or product (if applicable)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cohort A
Head and Neck Patients; Photon or Proton Treatment with product
|
liquid skin protectant on skin to protect from radiation dermatitis
|
|
Cohort B
Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
|
liquid skin protectant on skin to protect from radiation dermatitis
|
|
Cohort C
Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
|
liquid skin protectant on skin to protect from radiation dermatitis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
compare radiation dermatitis severity
Time Frame: 3 months (+/- 1 month) following the completion of radiation therapy
|
To compare radiation dermatitis severity in irradiated skin protected by a liquid skin protectant (3M™ Cavilon™ Advanced Skin Protectant) that rapidly dries versus uncovered skin (internal control) as determined by a panel.
|
3 months (+/- 1 month) following the completion of radiation therapy
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17-006813
- ROR1603 (Other Identifier: Mayo Clinic)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.